We are live on ! Find out more
KIN

Kindred Biosciences, Inc.
KIN

Delisted

KIN was delisted on the 27th of August, 2021.

75 hedge funds and large institutions have $233M invested in Kindred Biosciences, Inc. in 2019 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 33 increasing their positions, 16 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

106% more repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 16

30% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 10

4% more funds holding

Funds holding: 7275 (+3)

4% less capital invested

Capital invested by funds: $242M → $233M (-$8.65M)

50% less funds holding in top 10

Funds holding in top 10: 21 (-1)

Holders
75
Holders Change
+3
Holders Change %
+4.17%
% of All Funds
1.62%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
13
Increased
33
Reduced
16
Closed
10
Calls
$437K
Puts
Net Calls
+$437K
Net Calls Change
+$478K
Name Holding Trade Value Shares
Change
Change in
Stake
PWAM
1
Park West Asset Management
California
$61.8M +$7.53M +741,840 +12%
AI
2
Ariel Investments
Illinois
$24M +$6.31M +621,234 +31%
BlackRock
3
BlackRock
New York
$18M +$1.26M +124,329 +7%
Vanguard Group
4
Vanguard Group
Pennsylvania
$15.4M +$2.58M +254,538 +18%
Adage Capital Partners
5
Adage Capital Partners
Massachusetts
$15.1M +$6.25M +615,000 +59%
Dimensional Fund Advisors
6
Dimensional Fund Advisors
Texas
$12.3M -$370K -36,394 -3%
Renaissance Technologies
7
Renaissance Technologies
New York
$11.2M +$1.26M +123,810 +11%
Morgan Stanley
8
Morgan Stanley
New York
$10.4M -$6.98M -686,892 -38%
Deutsche Bank
9
Deutsche Bank
Germany
$7.88M +$8.05M +792,364 +1,170%
GIM
10
Granahan Investment Management
Massachusetts
$6.52M -$752K -74,072 -9%
State Street
11
State Street
Massachusetts
$4.9M +$806K +79,345 +17%
SAM
12
Silverback Asset Management
North Carolina
$4.58M +$2.2M +216,809 +77%
GAI
13
General American Investors
New York
$4.12M
Northern Trust
14
Northern Trust
Illinois
$3.87M +$503K +49,549 +13%
Alyeska Investment Group
15
Alyeska Investment Group
Illinois
$3.76M +$4.17M +410,212 New
Geode Capital Management
16
Geode Capital Management
Massachusetts
$3.63M +$572K +56,299 +17%
Allianz Asset Management
17
Allianz Asset Management
Germany
$3.11M +$943K +92,850 +38%
Millennium Management
18
Millennium Management
New York
$2.5M +$2.77M +272,547 New
Wells Fargo
19
Wells Fargo
California
$1.69M -$85.8K -8,453 -4%
PVAM
20
Pacific View Asset Management
California
$1.67M -$942K -92,802 -34%
Fuller & Thaler Asset Management
21
Fuller & Thaler Asset Management
California
$1.41M -$28.6K -2,820 -2%
SIA
22
Sit Investment Associates
Minnesota
$1.07M +$597K +58,800 +102%
RCMNY
23
Rubric Capital Management (New York)
New York
$1.06M +$1.18M +115,992 New
Bank of New York Mellon
24
Bank of New York Mellon
New York
$1.02M +$96.9K +9,545 +9%
Charles Schwab
25
Charles Schwab
California
$727K +$133K +13,072 +20%

KIN Hedge Fund Activity: Q1 2019 in Review

75 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in Kindred Biosciences, Inc. (KIN) for Q1 2019, worth a combined $233M — down 3.6% from $242M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new KIN positions and 10 closed out — a net gain of 3 holders — while 33 added to existing stakes and 16 trimmed.

The largest buyer was Deutsche Bank, adding an estimated $8.05M. The largest seller was Morgan Stanley, cutting an estimated $6.98M.

  • 75 institutional investors held Kindred Biosciences, Inc. (KIN) as of Q1 2019, up from 72 in Q4 2018.
  • Funds reported $233M of Kindred Biosciences, Inc. stock for Q1 2019, down 3.6% quarter-over-quarter.
  • 13 funds opened new Kindred Biosciences, Inc. positions in Q1 2019 and 10 closed out, a net change of +3 holders.
  • The largest Kindred Biosciences, Inc. buyer in Q1 2019 was Deutsche Bank, an estimated $8.05M added.
  • The largest Kindred Biosciences, Inc. seller in Q1 2019 was Morgan Stanley, an estimated $6.98M sold.

Based on aggregated 13F filings for Q1 2019.